This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Primary agammaglobulinaemia원발성 무감마글로불린혈증

ICD-10: D80.0 | Synonyms: Primary antibody deficiency (PAD), congenital agammaglobulinemia

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description of agammaglobulinemia

The history of primary agammaglobulinemia begins with the pioneering report by Ogden C. Bruton in 1952, who found that the immunoglobulin fraction was absent on serum electrophoresis in an 8-year-old boy suffering from recurrent pneumonia and bacterial infections, and brought about clinical improvement by administering gamma globulin. This report, as the first clinical case demonstrating the importance of humoral immunity, made an important contribution to the history of immunology.

Development of the classification system for primary immunodeficiencies

The classification system for primary immunodeficiency diseases developed from the 1960s to the 1980s. The World Health Organization (WHO) began systematically classifying primary immunodeficiency diseases in the 1970s, and since then the International Union of Immunological Societies (IUIS) has regularly updated the classification.

Advances in molecular genetics

With identification of the BTK gene in 1993 and the subsequent sequential discovery of various causative genes such as IGHM, IGLL1, BLNK, CD79A, and CD79B, the molecular basis of primary agammaglobulinemia was established. This confirmed that primary agammaglobulinemia is not a single disease but a heterogeneous group of genetic disorders with a common phenotype.

Developments in Korea

In Korea, a diagnostic system for primary agammaglobulinemia was established along with the development of pediatric immunology in the 1980s–1990s. With the launch of the Korean primary immunodeficiency patient registry project, understanding of the patient population and treatment support gradually became more systematic.

2. Causes

Primary pathogenesis

Primary agammaglobulinemia refers to a condition in which immunoglobulins are not produced, or are produced in extremely small amounts, because of a genetic defect, without secondary causes (malignancy, drugs, protein loss, etc.). The modifier 'primary' distinguishes it in this respect from secondary agammaglobulinemia.

B-cell developmental defects

The common etiology of primary agammaglobulinemia is a block in B-cell development in the bone marrow. Various genetic abnormalities, such as BTK gene variants (XLA) and IGHM, IGLL1, CD79A, CD79B, and BLNK variants, block development from pro-B cells to mature B cells, causing the common agammaglobulinemia phenotype.

Cases of unknown cause

In some patients, no pathogenic variant is found in the currently known causative genes. This may be due to undiscovered causative genes, deep intronic variants, epigenetic dysregulation, etc., and research is ongoing.

3. Genetics

Coexistence of multiple inheritance patterns

The inheritance patterns of primary agammaglobulinemia include X-linked recessive (XLA, BTK variants), autosomal recessive (IGHM, IGLL1, CD79A/B, BLNK variants, etc.), and, rarely, autosomal dominant forms. The most common cause of primary agammaglobulinemia is XLA (about 85% of male patients), and the rest are due to various autosomal gene variants.

Sporadic variants

40–50% of all agammaglobulinemia patients are sporadic cases due to de novo variants without a family history. This is an important consideration in calculating recurrence risk during genetic counseling.

Importance of genetic testing

Accurate identification of the causative gene in primary agammaglobulinemia is essential for genetic counseling, prenatal diagnosis, and establishing a treatment strategy. Distinguishing XLA from autosomal recessive variants directly affects family planning.

4. General epidemiology

Worldwide incidence

The overall incidence of primary agammaglobulinemia is estimated at about 1 in 100,000–200,000 male newborns. It belongs to the most severe forms of primary antibody deficiency and is rarer than common variable immunodeficiency (CVID).

Sex distribution

Because XLA accounts for most primary agammaglobulinemia, there is traditionally a male predominance (about 4:1), but as diagnoses of autosomal recessive forms increase, the proportion of female patients is also increasing.

Age at diagnosis

In most cases symptoms first appear at 6–18 months of age, but mild cases are sometimes diagnosed after school age. The average time to diagnosis is 1–5 years, so education and increased awareness among health professionals are needed for early diagnosis.

Status in Korea

Patients with primary agammaglobulinemia in Korea are registered in the integrated rare disease system, but accurate prevalence statistics are limited. Analysis of Health Insurance Review & Assessment Service (HIRA) data estimates the number of patients with D80 codes at tens to hundreds per year. The number of diagnoses is gradually increasing along with improvements in diagnostic technology.

5. Pathophysiology

Block in B-cell developmental stages

The core pathophysiology of primary agammaglobulinemia is a block of B-cell development at a specific stage in the bone marrow. Normal B-cell development proceeds from hematopoietic stem cell→common lymphoid progenitor→pro-B cell→pre-B cell→immature B cell→mature B cell. Variants in genes such as BTK, IGHM, BLNK, and CD79A/B block the transition from pro-B to pre-B cells.

Consequences of complete absence of immunoglobulin production

Because mature B cells and plasma cells are nearly or completely absent, virtually no immunoglobulin of any class (IgG, IgA, IgM, IgE, IgD) is produced. Antibody-mediated immunity is completely lost, so defense against encapsulated bacteria and viruses (especially enteroviruses) is severely impaired.

Preservation of T-cell function

Primary agammaglobulinemia is a pure B-cell developmental defect, and T-cell function is preserved as normal. In this respect it differs from severe combined immunodeficiency (SCID), which has defects in both T and B cells. Because T-cell-dependent immunity (cellular immunity) is preserved, defense against some viral and fungal infections is maintained.

6. Symptoms

Characteristic clinical features

Repeated and recurrent bacterial infections after 6–18 months of age are characteristic. Pneumonia, sinusitis, otitis media, bacteremia, meningitis, and arthritis are the main infection patterns. Compared with ordinary children, the infections are more severe and more frequent; they respond to antibiotic treatment but recur.

Enterovirus-related complications

Before immunoglobulin replacement therapy is started, or when treatment is insufficient, chronic meningoencephalitis caused by enteroviruses (echovirus, coxsackievirus) can occur. Delayed diagnosis leads to permanent neurological damage. Enterovirus-induced dermatomyositis-like syndrome is also a characteristic complication.

Other infections

Chronic diarrhea due to Giardia lamblia, septic arthritis due to Campylobacter, and arthritis due to Mycoplasma may occur. Susceptibility to common opportunistic infections (Pneumocystis jirovecii, Candida, etc.) is relatively low.

7. Signs

Physical examination findings

Atrophic or absent tonsils and nonpalpable peripheral lymph nodes are characteristic. Abnormal chest auscultation due to recurrent pneumonia, bronchiectasis, and findings of chronic rhinorrhea and sinusitis. Growth retardation is often absent after long-term treatment, but growth impairment may occur in patients who had a long period of recurrent infections before treatment.

Laboratory findings

Serum IgG < 2 g/L (or below 2 SD of the lower limit of normal for age), IgA and IgM extremely low or undetectable. Peripheral blood CD19+ B cells < 2% or absolute count < 0.1 × 10⁹/L. T-cell (CD3+, CD4+, CD8+) counts and function normal. Absent specific antibody response after vaccination.

Imaging findings

Chest CT: bronchiectasis and bronchiolectasis due to recurrent pneumonia. Head and neck CT: chronic sinusitis, mastoiditis. Joint X-ray: findings of bacterial or Mycoplasma arthritis.

8. Screening

Warning signs

Among the warning signs of primary immunodeficiency presented by the Jeffrey Modell Foundation and IUIS, the following are particularly relevant: two or more pneumonias in one year, four or more episodes of otitis media, recurrent deep skin/organ infections, two or more episodes of sepsis, infections not responding to antibiotic treatment, and a family member with primary immunodeficiency.

Immunoglobulin quantification and B-cell analysis

Quantification of serum IgG, IgA, and IgM and lymphocyte subset testing by flow cytometry (CD19+ B-cell percentage/absolute count, CD3+ T-cell analysis) are the basic screening tests. Results must be interpreted against age-specific normal values.

BTK protein expression test

BTK protein expression is measured in monocytes (CD14+) by flow cytometry to rapidly determine whether XLA is present.

9. Diagnosis

ESID/PAGID diagnostic criteria

Diagnosis of primary agammaglobulinemia is made by integrating criteria such as ① marked reduction of serum IgG, IgA, and IgM, ② marked reduction or absence of peripheral blood B cells, ③ exclusion of secondary causes, and ④ confirmation of a causative gene variant.

Molecular genetic diagnosis

BTK gene analysis (Sanger or NGS), a primary immunodeficiency gene panel (including IGHM, IGLL1, CD79A, CD79B, BLNK, PIK3R1, etc.), and whole exome/genome analysis are performed in a stepwise manner.

Exclusion of secondary causes

Secondary hypogammaglobulinemia due to malignant lymphoma, chronic lymphocytic leukemia, protein-losing enteropathy, nephrotic syndrome, or use of immunosuppressants must be excluded.

10. Treatment

Immunoglobulin replacement therapy

Intravenous immunoglobulin (IVIG, 400–600 mg/kg/3–4 weeks) or subcutaneous immunoglobulin (SCIG) is the standard treatment. The goal is maintaining an IgG trough level of 8 g/L or higher, with a target of 10 g/L or higher when there are pulmonary complications such as bronchiectasis. IgRT should be started immediately upon diagnosis and continued for life.

Antibiotic therapy

Early antibiotic treatment is essential for acute infections. Chest physiotherapy and airway clearance techniques for bronchiectasis are also used concurrently.

Live vaccines contraindicated

Live vaccines such as oral polio vaccine (OPV), varicella vaccine, and BCG are absolutely contraindicated in primary agammaglobulinemia. Caution is also needed regarding the use of live vaccines by family members.

11. Prognosis

Dramatic difference in prognosis before and after treatment

Before the introduction of IgRT, most patients died in childhood from severe infectious complications. Patients now receiving regular IgRT survive into adulthood and can maintain a relatively normal quality of life.

Long-term complications and prognosis

When diagnosis is delayed, bronchiectasis, reduced lung function, and sequelae of central nervous system enterovirus infection may already have developed, in which case the long-term prognosis is poor. Chronic lung disease is the main cause of morbidity and mortality. With appropriate IgRT and infection management, life expectancy and quality of life can be kept close to normal.

12. Prevention

Family screening and genetic counseling

Genetic counseling and carrier testing are important in the families of diagnosed patients. When XLA is diagnosed, the mother's carrier status is checked and male siblings are screened. For autosomal recessive forms, siblings and parents are tested and a prenatal diagnosis plan is established.

Importance of early diagnosis

The key to prevention in primary agammaglobulinemia is starting IgRT immediately after early diagnosis. The longer the diagnostic delay, the more pulmonary complications and central nervous system damage accumulate, so increased awareness among health professionals is important.

Education on contraindication of live vaccines

Patients and caregivers must be educated about the absolute contraindication of live vaccines. Particular caution is needed regarding oral polio vaccine.

13. References

  1. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722-728.
  2. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96-128.
  3. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85(4):193-202.
  4. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199-227.
  5. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-1205.
  6. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-194.
  7. Ochs HD, Smith CIE, Puck JM. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. 3rd ed. Oxford University Press; 2013.
  8. Plebani A, Soresina A, Rondelli R, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221-230.
  9. Suri D, Rawat A, Singh S. X-linked agammaglobulinemia. Indian J Pediatr. 2016;83(4):331-337.
  10. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease. J Allergy Clin Immunol. 2006;117(4 Suppl):S525-553.
  11. Aghamohammadi A, Moin M, Karimi A, et al. Immunologic evaluation of patients with primary antibody deficiencies. J Investig Allergol Clin Immunol. 2010;20(6):481-493.
  12. Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019;7(6):1763-1770.